In the Media: For the First Time in Decades, We Have a New Kind of Schizophrenia Drug
Dr. Ann K. Shinn shares insight on a new antipsychotic medication created to treat schizophrenia.
Ann Shinn Related Content
Type of Content
In the Media: A New Kind of Drug for Schizophrenia Promises Fewer Side Effects
Listen to Dr. Ann K. Shinn explain how certain medications for schizophrenia work by targeting dopamine neurotransmission.
In the Media: Revolutionary Drug for Schizophrenia Wins U.S. Approval
Dr. Ann K. Shinn provides independent feedback on the approval of a new medication for treating schizophrenia.
In the Media: Will ‘Game-Changer’ Antipsychotic Live Up to the Hype?
Dr. Ann K. Shinn reacts to the results of a clinical trial examining the effectiveness of a new medication for treating schizophrenia.
In the Media: Gut Signature for Treatment-Resistant Schizophrenia?
Dr. Ann K. Shinn offers independent feedback to a new study looking at the gut microbiome differences in adults living with treatment-resistant schizophrenia.
In the Media: Positive Phase 3 Results for Novel Antipsychotic in Schizophrenia
Dr. Ann K. Shinn comments on the findings of a clinical trial examining a new antipsychotic medication.
Dr. Ann Shinn Receives McMahon Mentoring Award
Ann K. Shinn, MD, MPH, is the 2022 recipient of the Thomas A. McMahon Mentoring Award from the Harvard-MIT Program in Health Sciences and Technology (HST). Shinn is the director of clinical research for McLean Hospital’s Schizophrenia and Bipolar Disorder Research Program. The McMahon Award was...
In the Media: MNT Investigates – Second-Generation Antipsychotic Drugs for Schizophrenia
Dr. Ann K. Shinn and others discuss the differences and similarities between first-generation and second-generation antipsychotics.
